TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05065372
Drug: Iohexol 300 Mg/mL Injectable Solution
Normalized name: iohexol 300 mg/mL injectable solution
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diagnostic aid/agent used to measure glomerular filtration rate
Study: NCT06448143
Drug: Indigotindisulfonate sodium 0.8% injection
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental contrast dye for diagnostic procedures, commonly used as a visualization aid in pelvic and abdominal surgeries, as well as for evaluating ureteral patency.
Study: NCT05436535
Drug: Vanicream- Dupilumab-naïve
Normalized name: Vanicream Diaper Rash
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dupilumab-naïve AD participants will apply Vanicream at least twice daily to the specified target skin area over two time periods during the study. First, they will apply starting at Day 0 through Day 7. They will resume application starting at their penultimate visit (Day 140-196) through the End of Study Assessment.
Study: NCT05436535
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On Day 7, all dupilumab-naïve AD participants will begin applying triamcinolone 0.1% ointment (provided by the study) twice daily to the specified target area. Additionally, dupilumab-naïve AD participants will apply triamcinolone 0.1% ointment twice daily to active lesions on non-sensitive, non-target skin.~Between Day 35 and Day 140, dupilumab-naïve AD topical steroid responsive (EASI ≤ 7) participants will apply triamcinolone 0.1% ointment (provided by the study) once or twice daily, per clinician discretion, to the specified target area. Additionally, participants will apply triamcinolone 0.1% ointment once or twice daily, per clinician discretion, to active lesions on non-sensitive skin body wide.~Between Day 35 and Day 140, dupilumab-naïve topical steroid non-responder (EASI \>7) participants may apply triamcinolone 0.1% ointment as needed to active lesions on non-sensitive, non-target skin.
Study: NCT05436535
Drug: Vanicream- Active
Normalized name: Vanicream Diaper Rash
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-AD control participants will apply Vanicream at least twice daily to the specified target skin area over two time periods during the study. First, they will apply starting at Day 0 through Day 7. They will resume application starting at Day 140 through the End of Study Assessment Visit.
Study: NCT05436535
Drug: Vanicream- Experienced Dupilumab
Normalized name: Vanicream Diaper Rash
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Long-term dupilumab participants will apply Vanicream at least twice daily to the specified target skin area over two time periods during the study. First, they will apply starting at Day 0 through Day 7. They will resume application starting at Day 140 through the End of Study Assessment Visit.
Study: NCT05685602
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05685602
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT06311682
Drug: Tralokinumab + TCS
Normalized name: tralokinumab
DrugBank: Tralokinumab (DB12169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The trial medication will be given under the skin (SC). Dose and dosing frequency for each subject will depend on the subject's body weight. Subjects who will receive treatment every two weeks will receive a loading dose corresponding to a double dose at baseline. Subjects who will receive treatment every 4 weeks will receive a staggered loading dose at baseline and Week 2. After the loading dose, they will continue to receive treatment every 4 weeks. The dose and dosing frequency will be adjusted according to the subject's body weight at weeks 16, 32, 52, 64, 88, 112, 136, 160, and 184.
Study: NCT05323955
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administer per current package insert based on site standard of care guidelines
Study: NCT05323955
Drug: Trastuzumab Emtansine (T-DM1)
Normalized name: T-DM1
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administer per current package insert based on site standard of care guidelines
Study: NCT05323955
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administer per current package insert based on site standard of care guidelines
Study: NCT05323955
Drug: Tucatinib
Normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300 mg orally twice daily (21 Day Cycle)
Study: NCT05714683
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All participants will be treated with oral semaglutide for 26 weeks according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS. The prescription of semaglutide will be separated from the decision to include the participant in the study.
Study: NCT05469347
Drug: Alirocumab
Normalized name: Alirocumab
DrugBank: Alirocumab (DB09302)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A 600 mg dose of alirocumab (which is equivalent to 8mg/kg for a 75kg patient) will be administered once via IV over an approximately 30 ± 10 minute infusion using an infusion pump.
Study: NCT05968599
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: As provided in real-world setting
Study: NCT05968599
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: As provided in real-world setting
Study: NCT06062745
Drug: 18F-fluciclovine
Normalized name: fluciclovine (18F)
DrugBank: Fluciclovine (18F) (DB13146)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 18F-fluciclovine is a radiotracer targeting amino-acid transporters.Radiotracers are compounds or drugs that are attached to small amounts of a radioactive substance to make images of processes that are happening in the body
Study: NCT06250335
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV
Study: NCT06250335
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV
Study: NCT04438213
Drug: Ertugliflozin
Normalized name: Ertugliflozin
DrugBank: Ertugliflozin (DB11827)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
Study: NCT04438213
Drug: Metolazone
Normalized name: Metolazone
DrugBank: Metolazone (DB00524)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
Study: NCT05222971
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab 1,500 mg IV on Day 1~Every 4 weeks
Study: NCT05222971
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300 mg twice daily~Every 4 weeks
Study: NCT06394167
Drug: VX-993
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for IV administration.
Study: NCT04616027
Drug: PF-06882961 20 mg
Normalized name: cytarabine
DrugBank: PF-06882961 (DB16043)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PF-06882961 20 mg single oral dose provided in tablet form administered in a fed state on Day 1
Study: NCT04614441
Drug: OFEV®
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nintedanib
Study: NCT06427330
Drug: Inotuzumab ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1. st dose is given after D+60：inotuzumab 0.3mg/m2~2. nd dose is given after 1 month：inotuzumab 0.6mg/m2
Study: NCT06550271
Drug: Rapamycin
Normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rapamycin in 2 different dosage forms (compounded and generic)
Study: NCT06441045
Drug: Double Dose of Third-generation EGFR-TKI
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double Dose of Third-generation EGFR-TKI
Study: NCT06441045
Drug: Intrathecal Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intrathecal Pemetrexed
Study: NCT06278402
Drug: Tofacitinib
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tofacitinib 5mg twice daily for treatment of alopecia areata, totalis and universalis.
Study: NCT06338683
Drug: Olanzapine 2.5 MG
Normalized name: olanzapine 2.5 MG
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral olanzapine 2.5 mg once daily at bedtime until disease progression
Study: NCT06338683
Drug: Standard anti-tumor treatment
Normalized name: G 1 (anti-tumor agent)
DrugBank: LNS-8801 (DB18091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinicians choose the appropriate standard antitumor drug therapy based on the patient's specific situation
Study: NCT04797156
Drug: High Dose Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg/kg IV TXA
Study: NCT04797156
Drug: Low Dose Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg/kg IV TXA
Study: NCT04797156
Drug: Tranexamic acid Topical
Normalized name: azelate / tranexamic acid Topical Cream
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2g topical TXA
Study: NCT05239546
Drug: Dostarlimab
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive Dostarlimab 500 mg IV every 3 weeks for 9 cycles followed by 1000 mg every 6 weeks for 12 cycles until 2 years
Study: NCT06177041
Drug: M108 monoclonal antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: M108 monoclonal antibody will be administered as a minimum 2-hour IV infusion.
Study: NCT06177041
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin will be administered as a 2-hour IV infusion.
Study: NCT06370273
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10mg once daily via oral ingestion
Study: NCT06370273
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2.5mg twice daily via oral ingestion
Study: NCT06370273
Drug: Enoxaparin Injectable Solution
Normalized name: enoxaparin Injectable Solution
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg once daily via subcutaneous injection
Study: NCT06370273
Drug: Tinzaparin Injectable Solution
Normalized name: tinzaparin Injectable Solution
DrugBank: Tinzaparin (DB06822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4500 IU once daily via subcutaneous injection
Study: NCT06370273
Drug: Dalteparin Injectable Solution
Normalized name: dalteparin Injectable Solution
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 IU once daily via subcutaneous injection
Study: NCT06370273
Drug: Fondaparinux Injectable Product
Normalized name: fondaparinux Injectable Product
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg once daily via subcutaneous injection
Study: NCT05266027
Drug: Nalbuphine Sebacate (Naldebain)
Normalized name: sebacate
DrugBank: Dinalbuphine sebacate (DB15341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine Sebacate (Naldebain) 2mL/150mg would be intramuscularly injected during knee arthroplasty surgery.
Study: NCT05382091
Drug: naltrexone implant
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3.6 g per implant set each containing 60% naltrexone
Study: NCT06035224
Drug: AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AK104 (10mg/kg ,Q3W，intravenously) plus lenvatinib(\<60kg，8 mg qd；≥60kg，12mg qd, orally.
Study: NCT04078139
Drug: The RP group
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 10 ml 1% ropivacaine and 10 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
Study: NCT06325982
Drug: Triethanolamine cream
DrugBank: Trolamine (DB13747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triethanolamine cream retention enema was given once every night before going to bed during radiotherapy until the end of radiotherapy. Triethanolamine cream retention enema was given once before going to bed the day after radiotherapy for 3 months.~Preparation method: Pull out the syringe piston, add 15ml triethanolamine cream, add 30ml normal saline, gently pat, shake well.~Specific methods of retention enema: at night before going to bed, empty urine and feces, prepare enema liquid into the syringe, connect the special catheter, and insert the other end of the special catheter into the anus (the special catheter can be applied with lubricant such as tea oil before insertion). The patient remained prone and semi-seated. Use a special catheter, insert a special catheter about 15cm from the anus, and inject enteral liquid while withdrawing, so that the liquid is retained in the rectum; The above treatment was performed before bed and retained overnight.
Study: NCT05148546
Drug: Neoadjuvant nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive 2 cycles of nivolumab 360mg (arm A and C) or 3mg/kg (arm B) every 3 weeks followed by a nephrectomy.
Study: NCT05201469
Drug: VIB4920
Normalized name: PROTEIN VIB4920 (RECOMBINANT HUMAN TENASCIN C CD40 LIGAND-BINDING THIRD FIBRONECTIN TYPE III DOMAIN) FUSION PROTEIN WITH PEPTIDE (SYNTHETIC 19-AMINO ACID LINKER) FUSION PROTEIN WITH TENASCIN C CD40 LIGAND-BINDING THIRD FIBRONECTIN TYPE III DOMAIN (HUMAN
DrugBank: Dazodalibep (DB19025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1500 mg of VIB4920 at Weeks 0, 2, 4, 8, 12, 16, 20, and 24 while continuing on MMF and prednisone
Study: NCT04871269
Drug: Dronabinol
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dronabinol
Study: NCT05148546
Drug: Neoadjuvant ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive 2 cycles of ipilimumab 1mg/kg every 3 weeks followed by a nephrectomy.
Study: NCT05148546
Drug: Neoadjuvant relatlimab
Normalized name: Relatlimab
DrugBank: Relatlimab (DB14851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 2 cycles of relatlimab 360mg every 3 weeks followed by a nephrectomy.
Study: NCT05223335
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 75 mg/day
Study: NCT05223335
Drug: Prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 60 mg bolus then 10 mg daily
Study: NCT05223335
Drug: Tricagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180 mg bolus then 90 mg twice daily
Study: NCT05517421
Drug: Batoclimab
Normalized name: Batoclimab
DrugBank: Batoclimab (DB16104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
Study: NCT06278779
Drug: Esketamine group
Normalized name: esketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The recommended dosing for Spravato is:~Weeks 1-4:~Starting Day 1 dose:~\< 65 years: 56 mg~≥ 65 years: 28 mg~Subsequent doses:~28 mg (≥ 65 years), 56 mg or 84 mg twice weekly~Weeks 5-8:~28 mg (≥ 65 years), 56 mg or 84 mg once weekly~From Week 9:~28 mg (≥ 65 years), 56 mg or 84 mg every 2 weeks or once weekly
Study: NCT06232863
Drug: BH009
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Every 28 days constitutes a treatment cycle, and administration on day 1, day 8, day 15 of each cycle
Study: NCT05774275
Drug: Anti-PD-1 monoclonal antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg, d1, q3w
Study: NCT06278779
Drug: Racemic ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Typically, dosing will begin at the standard dose of 0.5 mg/kg and adjusted as needed using an ascending dose titration schedule:~1. 0.5 mg/kg~2. 0.6 mg/kg~3. 0.75 mg/kg~4. 0.9 mg/kg~5. Further increments by 0.1-0.2 mg/kg, up to max 1.5 mg/kg
Study: NCT06282848
Drug: Atropine 0.05%
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical application
Study: NCT03962062
Drug: Moxidectin
Normalized name: moxidectin
DrugBank: Moxidectin (DB11431)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg tablets
Study: NCT04890431
Drug: Oxygen
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oxygen treatment (5 L/minute for 30 minutes by nasal cannula, twice/day)
Study: NCT05410418
Drug: Mosunetuzumab
Normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosunetuzumab is administered subcutaneously using a step-up dosing strategy. The initial dose on C1D1 will be 5 mg, and doses thereafter will be 45 mg.
Study: NCT05410418
Drug: Polatuzumab vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Polatuzumab vedotin is administered intravenously over 90 minutes for the initial dose, and over 30 minutes thereafter.
Study: NCT05798403
Drug: Solifenacin Succinate Tablets
Normalized name: Solifenacin Succinate Tablets
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During the study, participants will take Solifenacin Succinate. The acupuncture points are the same as the electroacupuncture group, without the insertion of needles. The procedures, electrode positions and other treatment settings are the same as the electroacupuncture group, without the skin penetration, power output or needle manipulation of the de qi. At the end of the treatment, the acupuncturist will press the acupuncture point with a dry cotton ball to allow the patient to feel the needlesbeing pulled out.
Study: NCT05816343
Drug: Orlistat
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat is an inhibitor of gastric and pancreatic lipases and can reduce dietary fat absorption by 30%. Orlistat at a dose of 2 capsules (each containing 60 mg of active drug) three times a day with each meal (a total dose of 360 mg daily).
Study: NCT06082167
Drug: Zanzalintinib
Normalized name: Zanzalintinib
DrugBank: Zanzalintinib (DB17525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified doses on specified days
Study: NCT04885855
Drug: Sofosbuvir 400 MG
Normalized name: sofosbuvir 400 MG
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir is a direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5B (NS5B)
Study: NCT04885855
Drug: Ravidasvir 200mg
Normalized name: Ravidasvir
DrugBank: Ravidasvir (DB15652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ravidasvir is an investigational direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5A (NS5A)
Study: NCT05918913
Drug: Revumenib
Normalized name: Revumenib
DrugBank: Revumenib (DB18515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revumenib administered orally every 12 hours.
Study: NCT05380752
Drug: TPOXX IV (Tecovirimat Injection, 10 mg/mL)
Normalized name: Tpoxx
DrugBank: Tecovirimat (DB12020)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV solution (10 mg/mL) must be diluted with 2 parts 0.9% normal saline or 5% dextrose solution prior to dosing. Once diluted, the drug product should be stored at 2-8°C (36-46°F) and used as soon as possible (i.e., not more than 24 hours after dilution). Given via an IV infusion pump over a 6 hour period, twice daily, and for up to 7 days, or until the physician determines oral TPOXX may be given
Study: NCT05694013
Drug: Atezolizumab SC
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive atezolizumab SC for 16 cycles (cycle length = 21 days)
Study: NCT05135663
Drug: NS-089/NCNP-02
DrugBank: Brogidirsen (DB18884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The same dose administered in as Part 2 of Study NCNP/DMT02 (40 mg/kg) will be administered once weekly for 216 weeks (The total treatment period is 240 weeks including Part2 of Study NCNP/DMT02).
Study: NCT05135663
Drug: NS-089/NCNP-02
DrugBank: Brogidirsen (DB18884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The same dose administered in as Part 2 of Study NCNP/DMT02 (80 mg/kg) will be administered once weekly for 216 weeks (The total treatment period is 240 weeks including Part2 of Study NCNP/DMT02).
Study: NCT04765059
Drug: Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomized patients will receive oral dose of osimertinib with intravenous (IV) pemetrexed plus either IV cisplatin or IV carboplatin
Study: NCT04765059
Drug: Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
Normalized name: Cisplatin for Injection
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomized patients will receive oral dose of placebo matching osimertinib with IV pemetrexed plus either IV cisplatin or IV carboplatin
Study: NCT06404775
Drug: mastalgia-oil, tamoxifen placebo
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: external mastalgia-oil 1 ml/d per breast plus oral tamoxifen placebo 10mg/d for 3 consecutive menstrual cycles